Patents Assigned to Theratechnologies Inc.
-
Publication number: 20050059604Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: ApplicationFiled: October 28, 2004Publication date: March 17, 2005Applicant: Theratechnologies Inc.Inventors: Krishna Peri, Serge Moffett, Daniel Abran
-
Patent number: 6864239Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: GrantFiled: March 27, 2003Date of Patent: March 8, 2005Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran
-
Publication number: 20040171534Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: ApplicationFiled: August 7, 2002Publication date: September 2, 2004Applicant: Theratechnologies, Inc.Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
-
Patent number: 6458764Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: September 3, 1999Date of Patent: October 1, 2002Assignee: Theratechnologies Inc.Inventors: Denis Gravel, Abdelkrim Habi, Paul Brazeau
-
Patent number: 6194384Abstract: The present invention relates to a long-acting galenical formulation of GRF peptides, GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.Type: GrantFiled: August 18, 1998Date of Patent: February 27, 2001Assignee: Theratechnologies, Inc.Inventors: Paul Brazeau, Denis Gravel
-
Patent number: 6106544Abstract: The present invention relates to a device for closing cutaneous wounds without sutures, which comprises a pair of three-dimensionally flexible strips adopted to be positioned on each side of a wound and formed of a plurality of laterally spaced apart elongated anchoring members extending side-by-side in succession and transversely of the wound and being interconnected in a three-dimensionally flexible manner to follow the lips of an open wound.Type: GrantFiled: November 30, 1998Date of Patent: August 22, 2000Assignee: Theratechnologies, Inc.Inventor: Paul Brazeau
-
Patent number: 6020311Abstract: The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: September 8, 1998Date of Patent: February 1, 2000Assignee: Theratechnologies, Inc.Inventors: Paul Brazeau, Denis Gravel
-
Patent number: 5939386Abstract: The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: August 23, 1996Date of Patent: August 17, 1999Assignee: Theratechnologies Inc.Inventors: Michel Ibea, Thierry Abribat, Paul Brazeau
-
Patent number: 5861379Abstract: The present invention relates to chimeric fatty body-pro-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-pro-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring one or several hydrophobic tails to the GRF, or by substituting one or several amino-acids by a pseudomicellar residue in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.Type: GrantFiled: August 23, 1996Date of Patent: January 19, 1999Assignee: Theratechnologies Inc.Inventors: Michel Ibea, Thierry Abribat, Paul Brazeau
-
Patent number: 5843123Abstract: The present invention relates to a device for closing cutaneous wounds without sutures, which comprises a pair of three-dimensionally flexible strips adopted to be positioned on each side of a wound and formed of a plurality of laterally spaced apart elongated anchoring members extending side-by-side in succession and transversely of the wound and being interconnected in a three-dimensionally flexible manner to follow the lips of an open wound.Type: GrantFiled: September 6, 1996Date of Patent: December 1, 1998Assignee: Theratechnologies Inc.Inventor: Paul Brazeau
-
Patent number: 5837204Abstract: A system for disinfecting the water lines of a dental unit is provided with first and second unidirectional check valves. Water at a first pressure is normally supplied to the water lines of the dental unit through the first check valve. A reservoir of liquid disinfectant can be pressurized at a second pressure higher than the first pressure by the air compressor already equipping the dental unit to supply disinfectant to the water lines of the dental unit through the second check valve. Liquid disinfectant is prevented from reaching the water supply line by the first check valve. In the same manner, when the reservoir is not pressurized, the second check valve prevents water from the water supply line from reaching the disinfectant.Type: GrantFiled: April 18, 1997Date of Patent: November 17, 1998Assignees: Universite de Montreal, Theratechnologies, Inc.Inventors: Andre Prevost, Jean Barbeau, Ludger Cote, Robert Charland, Gary Savage, Michel Swift
-
Patent number: 5834418Abstract: The present invention relates to a process for the preparation of porcine platelet-extract containing matured growth factors, which comprises the steps of: a) centrifuging whole porcine blood at about 1000 g to about 5000 g to isolate the platelets from the platelet-rich-plasma; b) resuspending the isolated platelets of step a) in Plasma-Lyte A and centrifuging to concentrate the platelets; c) washing the concentrated platelets of step b); d) lyophilizing the washed platelets of step c); whereby causing lysis of the platelets and producing the platelet extract in optimal amount.Type: GrantFiled: March 20, 1996Date of Patent: November 10, 1998Assignee: Theratechnologies, Inc.Inventors: Paul Brazeau, Thierry Abribat, Michel Ibea, Michele Boushira
-
Patent number: 5817627Abstract: The present invention relates to a long-acting galenical formulation of GRF peptides, pro-GRF and/or analogs thereof which comprises about 1 to about 100 mg of a GRF peptide, fragment or analog thereof pressed from about 1 to about 100 kg/mm.sup.2 in a tablet for parenteral administration, whereby these GRF peptides are released as the tablet is eroded.Type: GrantFiled: June 14, 1996Date of Patent: October 6, 1998Assignee: Theratechnologies Inc.Inventors: Paul Brazeau, Thierry Abribat, Michel Ibea
-
Patent number: 5798523Abstract: An apparatus for irradiating a biological substance with a substantially uniform quantity of radiation energy comprises a radiation-generating device for producing radiation energy, a support structure for receiving the biological substance, and a motorized mechanism for reciprocating the radiation-generating device along a given path whereby the biological substance receives radiation energy from the radiation-generating device at each passage of the radiation-generating device. A series of sensors lie into a given plane and are subjected to radiation energy from the radiation-generating device upon each passage of that radiation-generating device for sensing and measuring the quantity of radiation energy by surface unit passing through the given plane and reaching the biological substance. Finally the radiation-generating device and the motorized mechanism are de-energized when the measured quantity of radiation energy by surface unit has reached a predetermined value.Type: GrantFiled: July 19, 1996Date of Patent: August 25, 1998Assignee: Theratechnologies Inc.Inventors: Luc Villeneuve, Gerard Miller, Robert Bernier, Claude Laurendeau, Prabir Kumar Pal
-
Patent number: 5602924Abstract: The electronic stethoscope is designed to minimize the influence of the various types of noise while optimizing auscultation of the sounds of interest, and to enable a cardiologist to auscultate mechanical heart valves. It comprises a probe for sensing sounds of interest produced within a patient's body and for converting these sounds to an electric signal, and an audio amplifier and earphones for reproducing the sounds of interest in response to this electric signal.Type: GrantFiled: December 9, 1993Date of Patent: February 11, 1997Assignee: Theratechnologies Inc.Inventors: Jocelyn Durand, Louis-Gilles Durand, Marie-Claude Grenien
-
Patent number: D371604Type: GrantFiled: February 15, 1995Date of Patent: July 9, 1996Assignee: Theratechnologies Inc.Inventors: Garry Savage, Michel Swift